The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

2.

For patients with breast cancer receiving chemotherapy, exercise may help lessen the long-term side effects.

3.

High levels of traumatic stress found in caregivers of adult cancer patients

4.

Breast cancer-related fatigue: The benefits of adapted physical activity

5.

According to a study, breast cancer in Syrian refugees tends to be diagnosed at an earlier stage and with more advanced tumors.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot